samedan logo

 
 
spacer
home > ebr > winter 2003 > understanding drug-kinase interactions with surface plasmon resonance (spr)
PUBLICATIONS
European Biopharmaceutical Review

Understanding Drug-Kinase Interactions with Surface Plasmon Resonance (SPR)

Protein kinases (PKs) represent one of the largest known superfamilies of human proteins. A recent report identified 510 candidate PK genes on the basis of sequence homology (1). PKs play critical roles in almost all signal transduction pathways, such as post-receptor cascades (2). Upstream signalling events are relayed by the action of PKs, usually via their phosphorylation of key serine, threonine or tyrosine residues on target proteins, using ATP or GTP as phosphate donors (3). These functions are carried out by a 250 amino acid catalytic domain, which is conserved among and used to identify members of the PK superfamily (4). This domain consists of an N-terminal lobe that binds and orientates the ATP/GTP, and a larger C-terminal lobe, which binds to the target protein and catalyses the transfer of phosphate.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Robert Karlsson, Director of Biochemistry and Chemistry at Biacore AB

Robert Karlsson joined Biacore in 1986 as one of the first five scientists in the company. In Biacore he has held several positions in both R&D and marketing. Mr Karlsson is currently Director of the Biochemistry and Chemistry Department of Biacore R&D at Biacore AB, with responsibility for leading both operational activities and the strategic development in these disciplines. Mr Karlsson has over 25 years' experience in the pharmaceutical and biotech industry. He has published around 30 papers on different aspects of Biacore analysis including methodology papers on mapping, kinetics, thermodynamics and concentration analysis, as well as application oriented papers on drug screening and ADME assays.

spacer
Robert Karlsson
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

High Throughput Analytics Herald a Paradigm Shift in the Development of Biopharmaceuticals

Heilbronn/Dortmund August 2019: Biopharmaceuticals have revolutionized therapies of various diseases. In particular with regard to chronical and/or severe clinical conditions like multiple sclerosis, rheumatoid arthritis or cancer they are considered the future of treatment. Also economically biological drugs are on their way up: The global biopharmaceuticals market is anticipated to reach about 400 billion USD by 2025. Which strategic alignment will help best to fill a successful pipeline?
More info >>

White Papers

Protein Therapeutics

Reading Scientific Services Ltd (RSSL)


More info >>

 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

23-26 March 2020, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 23 – 26 March 2020. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement